All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a major concern when treating high-risk leukemias or myelodysplastic syndromes (MDS). The consensus for adults is that a second allo-HSCT is the most beneficial intervention for survival following relapse; however, data are lacking for pediatric age groups.1 Additionally, there is uncertainty on which prognostic factors best predict eligibility for, and survival following, a second transplant. Such data could provide physicians with more accurate patient stratification to better guide treatment.1
Akshay Sharma and colleagues aimed to provide clarity for pediatric patients, recently publishing their retrospective analysis in Bone Marrow Transplantation. The primary objective was to assess the association of prognostic factors and treatment options with post-relapse survival following allo-HSCT, in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and MDS. The authors also investigated the association of prognostic factors with receiving a second transplant.1 We summarize key findings below.
Table 1. Patient characteristics for primary cohort*
Characteristic |
N = 221 |
---|---|
≤10 years old, % |
63.3 |
Sex, % |
|
Diagnosis, % |
|
CR status at first allo-HSCT, % |
|
Haploidentical donor, % |
33.0 |
GvHD status, % |
|
≤6 months to relapse, % |
61.1 |
Year of relapse, % |
|
ALL, acute lymphoblastic leukemia; allo-HSCT, allogeneic stem cell transplant; AML, acute myeloid leukemia; CR1, first complete remission; CR2+, second or subsequent complete remission; GvHD, graft-versus-host disease; MDS, myelodysplastic syndromes. |
Following univariate analysis, it was reported that being in complete remission at first allo-HSCT, relapse after 6 months, history of GvHD following first allo-HSCT, and relapse within 2011–2018, were all factors associated with increased likelihood of receiving a second transplant (Table 2).
Table 2. Association of prognostic factors and receiving a second allo-HSCT*
Prognostic factors |
Univariate |
Multivariable |
||||
---|---|---|---|---|---|---|
N = 221, n |
2nd HSCT, % |
p value |
OR |
95 % CI |
p value |
|
CR at first allo-HSCT |
|
|
0.02 |
|
|
0.26 |
Relapse-free duration |
|
|
< 0.001 |
|
|
< 0.001 |
Chronic GvHD |
|
|
0.01 |
|
|
0.33 |
Year of first relapse |
|
|
< 0.001 |
|
|
< 0.001 |
allo-HSCT, allogeneic stem cell transplantation; CI, confidence interval; CR1, first complete remission; CR2+, second or subsequent complete remission; GvHD, graft-versus-host disease; OR, odds ratio. |
As highlighted in Table 2, following multivariable analysis, only a longer duration of remission (>6 months) after allo-HSCT, and undergoing first allo-HSCT in a more recent time period (2011–2018), were significantly associated with receiving a second allo-HSCT.
Following univariate analysis, it was found that being female, in first complete remission, having relapse after 6 months of first allo-HSCT and/or relapse in a recent time period were factors significantly associated with improved post-relapse survival. In terms of treatment, receiving a second allo-HSCT or donor lymphocyte infusion were also associated with improved survival (Table 3).
Table 3. Association of prognostic factors and treatment options with 3-year overall survival*
Prognostic factors |
Post-relapse survival |
|||||
---|---|---|---|---|---|---|
Univariate |
Multivariable |
|||||
N = 221 |
Alive, % |
p value |
HR |
95% CI |
p value |
|
Sex |
|
|
0.04 |
|
|
0.22 |
CR at first allo-HSCT |
|
|
0.01 |
|
|
0.07 |
Relapse-free duration |
|
|
< 0.001 |
|
|
< 0.001 |
Year of first relapse |
|
|
< 0.001 |
|
|
< 0.001 |
Treatment post-relapse |
|
|
< 0.001 |
|
|
< 0.001 |
HR, hazard ratio; DLI, donor lymphocyte infusion. |
Following a multivariable analysis, the only factors significantly associated with improved post-relapse survival were duration from first allo-HSCT to relapse, receiving a second allo-HSCT or DLI, and relapse in a more recent time period (Table 3).
Overall, this study demonstrated the survival benefit of a second allo-HSCT following relapse for patients of pediatric age with AML, ALL, and MDS. However, it was observed that duration of post-transplant remission was associated with likelihood of a second transplant, thus reducing the number of patients eligible for this treatment benefit.
Importantly, the authors reported patients who relapsed less than 6 months after allo-HSCT but received a second transplant had comparable overall survival with those who relapsed after 6 months. As such, it may be beneficial to include patients for a second allo-HSCT irrespective of their remission status.
Subscribe to get the best content related to MDS delivered to your inbox